These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 30342794)

  • 21. Serum concentrations of HGF and IL-8 in patients with active Graves' orbitopathy before and after methylprednisolone therapy.
    Nowak M; Siemińska L; Karpe J; Marek B; Kos-Kudła B; Kajdaniuk D
    J Endocrinol Invest; 2016 Jan; 39(1):63-72. PubMed ID: 26062519
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Graves' animal models of Graves' hyperthyroidism.
    Nagayama Y
    Thyroid; 2007 Oct; 17(10):981-8. PubMed ID: 17822377
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Age and stress as determinants of the severity of hyperthyroidism caused by Graves' disease in newly diagnosed patients.
    Vos XG; Smit N; Endert E; Brosschot JF; Tijssen JG; Wiersinga WM
    Eur J Endocrinol; 2009 Feb; 160(2):193-9. PubMed ID: 18974230
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antithyroid drug treatment for Graves' disease: baseline predictive models of relapse after treatment for a patient-tailored management.
    Masiello E; Veronesi G; Gallo D; Premoli P; Bianconi E; Rosetti S; Cusini C; Sabatino J; Ippolito S; Piantanida E; Tanda ML; Chiovato L; Wiersinga WM; Bartalena L
    J Endocrinol Invest; 2018 Dec; 41(12):1425-1432. PubMed ID: 29946800
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Perspectives in pharmacological management of Graves' hyperthyroidism and orbitopathy.
    Bartalena L; Lai A; Tanda ML
    Expert Rev Clin Immunol; 2008 May; 4(3):321-9. PubMed ID: 20476922
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Animal models of Graves' disease and Graves' orbitopathy.
    Nagayama Y; Nakahara M; Abiru N
    Curr Opin Endocrinol Diabetes Obes; 2015 Oct; 22(5):381-6. PubMed ID: 26181432
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Optimal management of Graves orbitopathy: a multidisciplinary approach.
    Soeters MR; van Zeijl CJ; Boelen A; Kloos R; Saeed P; Vriesendorp TM; Mourits MP
    Neth J Med; 2011; 69(7):302-8. PubMed ID: 21934174
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Epidemiology, management and outcomes of Graves' disease-real life data.
    Hussain YS; Hookham JC; Allahabadia A; Balasubramanian SP
    Endocrine; 2017 Jun; 56(3):568-578. PubMed ID: 28478488
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Frequency and characteristics of TBII-seronegative patients in a population with untreated Graves' hyperthyroidism: a prospective study.
    Vos XG; Smit N; Endert E; Tijssen JG; Wiersinga WM
    Clin Endocrinol (Oxf); 2008 Aug; 69(2):311-7. PubMed ID: 18208575
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Does infection initiate Graves disease? A population based 10 year study.
    Cox SP; Phillips DI; Osmond C
    Autoimmunity; 1989; 4(1-2):43-9. PubMed ID: 2491641
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The treatment of Graves' disease: current views and controversies].
    Orgiazzi J
    Presse Med; 2011 Dec; 40(12 Pt 1):1155-62. PubMed ID: 22078090
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Clinical aspects of hyperthyroidism in areas of different supplies of iodine. Results of a European prospective study].
    Reinwein D; Benker G; König MP; Pinchera A; Schatz H; Schleusener H
    Schweiz Med Wochenschr; 1987 Aug; 117(34):1245-55. PubMed ID: 3672070
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New-onset Graves' disease in the postpartum period.
    Goldstein AL
    J Midwifery Womens Health; 2013; 58(2):211-4. PubMed ID: 23590488
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epidemiology and prevention of Graves' ophthalmopathy.
    Wiersinga WM; Bartalena L
    Thyroid; 2002 Oct; 12(10):855-60. PubMed ID: 12487767
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Partial prediction of postpartum Graves' thyrotoxicosis by sensitive bioassay for thyroid-stimulating antibody measured in early pregnancy.
    Ide A; Amino N; Nishihara E; Kudo T; Ito M; Kimura Y; Tatsumi N; Yamazaki M; Miyauchi A
    Endocr J; 2016 Oct; 63(10):929-932. PubMed ID: 27432817
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Variation in the use of definitive treatment options in the management of Graves' disease: a UK clinician survey.
    Hookham J; Collins EE; Allahabadia A; Balasubramanian SP
    Postgrad Med J; 2017 Apr; 93(1098):198-204. PubMed ID: 27531964
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diagnosis and treatment of Graves' disease with particular emphasis on appropriate techniques in nuclear medicine. General state of knowledge.
    Prasek K; Płazińska MT; Królicki L
    Nucl Med Rev Cent East Eur; 2015; 18(2):110-6. PubMed ID: 26315874
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Evolution of diagnostic and therapeutic criteria in Graves' disease in Spain. Comparison of the results of 2 surveys in 1987 and 1995].
    Escobar Jiménez F; Luna López V; Fernández Soto ML; Quezada Charneco M; Glinoer D
    Med Clin (Barc); 1998 Sep; 111(6):205-10. PubMed ID: 9789225
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Endocrinological findings in endocrine orbitopathy].
    Hädecke J; Schneyer U
    Klin Monbl Augenheilkd; 2005 Jan; 222(1):15-8. PubMed ID: 15678394
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Simultaneous occurrence of subacute thyroiditis and Graves' disease.
    Hoang TD; Mai VQ; Clyde PW; Shakir MK
    Thyroid; 2011 Dec; 21(12):1397-400. PubMed ID: 22136271
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.